Information Provided By: 
Fly News Breaks for June 29, 2016
REGN
Jun 29, 2016 | 08:41 EDT
As noted earlier, Bernstein initiated coverage of Regeneron with an Outperform rating. The firm expects the sales of the company's Praluent drug to accelerate, and it believes that the shares have reached an attractive entry point following their steep decline since 2015. Target $400.
News For REGN From the Last 2 Days
REGN
Apr 26, 2024 | 08:41 EDT
Oppenheimer analyst Hartaj Singh raised the firm's price target on Regeneron to $1,175 from $1,125 and keeps an Outperform rating on the shares ahead of the Q1 earnings report on May 2. Oppenheimer believes the areas of focus will be the status and dynamics of the Eylea High Dose launch, questions around the impending Dupixent COPD PDUFA, the status of the two oncology approvals expected in 2024, updates on various pipeline projects in immunology and oncology, and comments on capital allocation and financial planning by the new CFO at the company.
REGN
Apr 25, 2024 | 07:28 EDT
